Canagliflozin offers modest weight benefits in obese people

12/10/2013 | MedPage Today (free registration)

Non-hyperglycemic obese and overweight patients who took any of three doses of canagliflozin lost more weight and attained modest BMI reductions compared with those in the placebo group, according to a study in the journal Obesity. However, researchers did not observe significant differences in triglycerides or HDL cholesterol between the groups.

View Full Article in:

MedPage Today (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
Winston-Salem, NC
Director of Product Planning Development; Market Planning, Innovation
Blue Cross Blue Shield of Massachusetts
Quincy , MA
Director, Payer Marketing
Avalere Health
Washington, DC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX